ライフサイエンスコーパス: pharmacotherapeutic

1 ited toward the discovery of a cocaine-abuse pharmacotherapeutic.

2 ure progression and are targeted by standard pharmacotherapeutics.

3 echanisms could represent a new paradigm for pharmacotherapeutics.

4 007 as a lead for discovery of cocaine-abuse pharmacotherapeutics.

5 posed to tissue-selective-and gender-neutral pharmacotherapeutics.

6 for which there are no universally effective pharmacotherapeutics.

7 be possible, facilitating the development of pharmacotherapeutics.

8 ence lifestyle modifications and advances in pharmacotherapeutics, a large percentage of patients sti

9 D risk factors, AD preclinical detection and pharmacotherapeutic action of AD symptoms.

10 a rapid timescale and also suggests that the pharmacotherapeutic actions of amphetamine for cocaine a

11 , and patients, yet the relevance of this to pharmacotherapeutic actions remains unresolved.

12 m with a rising incidence and morbidity, few pharmacotherapeutic advances have been made over the pas

13 h indicated its potential in developing as a pharmacotherapeutic against elastase-mediated pathologie

14 A diagnostic trial of a pharmacotherapeutic agent could be started in people wit

15 existing therapy has started the search for pharmacotherapeutic agents acting on alternative pathway

16 GBR-12909-like compounds may be useful pharmacotherapeutic agents for cocaine addiction.

17 ective benzyl phenylacetamides are candidate pharmacotherapeutic agents that could be used to minimiz

18 the mechanisms, risk factors, and offending pharmacotherapeutic agents that may cause drug-induced a

19 combination therapy and introduction of new pharmacotherapeutic agents.

20 Thus, pharmacotherapeutics aimed at enhancing cognitive functi

21 ith reduced cocaine intake, and propose that pharmacotherapeutics aimed at these complexes may have p

22 d glucose balance with current and potential pharmacotherapeutic and surgical interventions for the t

23 anisms should facilitate the design of novel pharmacotherapeutics and dedicated antidiabetes GI manip

24 nvasive imaging technology and data on novel pharmacotherapeutics and other therapeutic interventions

25 epidemiological, neuroimaging, pathological, pharmacotherapeutic, and clinical studies.

26 Moreover, PDM may represent a novel pharmacotherapeutic approach for cocaine addiction becau

27 transformation and suggest a potential novel pharmacotherapeutic approach to acute myeloid leukaemia.

28 ion in mitochondria may represent a rational pharmacotherapeutic approach to diseases with increased

29 Behavioral and pharmacotherapeutic approaches constitute two prominent

30 and peripheral circulations, and traditional pharmacotherapeutic approaches have not significantly af

31 n opens new directions in the development of pharmacotherapeutic approaches in the management of CHB.

32 Pharmacotherapeutic approaches limiting changes in KOPr/

33 f MIF in viral pathogenesis and suggest that pharmacotherapeutic approaches targeting MIF may hold pr

34 uture development of novel anti-inflammatory pharmacotherapeutic approaches to combat respiratory dis

35 ne axis in SSADH(-/-) mouse brain, effective pharmacotherapeutic approaches, preliminary gene-therapy

36 ology and even open new avenues for targeted pharmacotherapeutic approaches.

37 of the disease pathophysiology and alternate pharmacotherapeutic approaches.

38 y constitute a target for new diagnostic and pharmacotherapeutic approaches.

39 diseases with the E-pore peptide opens novel pharmacotherapeutic avenues in the diagnosis and managem

40 There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive,

41 Standard courses of pharmacotherapeutic cessation aids improve short-term ab

42 lding blocks for generating novel HS mimetic pharmacotherapeutics, diagnostic reagents, and biomateri

43 l, cannabidiol (CBD), has been shown to have pharmacotherapeutic efficacy for the treatment of schizo

44 Results from this study suggest that pharmacotherapeutic efficacy in schizophrenia treatment

45 g trauma and sepsis and in the assessment of pharmacotherapeutic efficacy.

46 ially, new leads toward the development of a pharmacotherapeutic for cocaine abuse and other disorder

47 ntagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse.

48 elp identify novel diagnostic biomarkers and pharmacotherapeutics for these disorders.

49 of alpha4beta2-nAChR can potentially be new pharmacotherapeutics for treatment of nicotine dependenc

50 ulation of axonal Ca(2+) stores may be a key pharmacotherapeutic goal in spinal cord injury.

51 Such oligonucleotide-derived pharmacotherapeutics have limitations in specificity for

52 Current narcolepsy pharmacotherapeutics include controlled substances with

53 otein SAP97 may represent a novel target for pharmacotherapeutic intervention in the treatment of coc

54 The combined cognitive-behavioral and pharmacotherapeutic intervention resulted in sustained a

55 is of the disease and offers new targets for pharmacotherapeutic intervention.

56 is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illn

57 Intensive lifestyle and pharmacotherapeutic interventions reduce the progression

58 ing, requires constant psychotherapeutic and pharmacotherapeutic interventions to minimize the potent

59 ial alternatives to current psychosocial and pharmacotherapeutic interventions, but identification of

60 the development of more targeted, effective pharmacotherapeutic interventions.

61 ms discovered in model organisms may lead to pharmacotherapeutic interventions.

62 not target opioid receptors or common opioid pharmacotherapeutics, it can be used in conjunction with

63 crease in Abeta secretion and respond to the pharmacotherapeutic modulation by anti-amyloidogenic com

64 ing this gatekeeper function may provide new pharmacotherapeutic opportunities to prevent the excessi

65 etiology of autism, few have translated into pharmacotherapeutic opportunities.

66 activation of PPARgamma may represent a new pharmacotherapeutic option for the treatment of opioid a

67 ess, leaving this patient population without pharmacotherapeutic options.

68 consists of androgen deprivation therapy by pharmacotherapeutic or surgical means.

69 physician's discretion, assisted by hospital pharmacotherapeutic or transfusion committees.

70 The data support the pharmacotherapeutic potential of PEDF as a neuroprotecta

71 Interventions such as aggressive pharmacotherapeutic prophylaxis to prevent relapse or re

72 y ill patients are treated with an extensive pharmacotherapeutic regimen.

73 but GC treatment may be associated with poor pharmacotherapeutic response or prognosis.

74 efore, may prove to be a putative target for pharmacotherapeutic strategies and cognitive-behavioral

75 Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, per

76 Mifepristone may be a valuable pharmacotherapeutic strategy for preventing relapse to a

77 First, pharmacotherapeutic studies using pancreatic tumor cell

78 disease and at the same time provide a novel pharmacotherapeutic target for a lung disease that to da

79 h, the results identify group II mGluRs as a pharmacotherapeutic target for craving and relapse preve

80 coupled receptors (GPCRs) and is a potential pharmacotherapeutic target for heart failure, hypertensi

81 tify the integrin alpha9beta1 as a potential pharmacotherapeutic target for inhibition of pathogenic

82 Thus, ADAM10 represents an important pharmacotherapeutic target for the treatment of cerebral

83 line receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abu

84 hypothesis that KORs may provide a promising pharmacotherapeutic target in the treatment of alcoholis

85 H2 is hence considered an important emerging pharmacotherapeutic target, the role of the DP receptor

86 er drugs, rendering this pathway a promising pharmacotherapeutic target.

87 ne injury in general, it forms an attractive pharmacotherapeutic target.

88 ase pathway of anandamide synthesis may be a pharmacotherapeutic target.

89 in the nucleus accumbens (NAc) as potential pharmacotherapeutic targets for treating cocaine additio

90 Ion channels are thus a major class of pharmacotherapeutic targets.

91 ous substrates should aid the development of pharmacotherapeutics that target individual MMPs.

92 opioid ligands may be useful as a potential pharmacotherapeutic to decrease drug abuse.

93 ogy, gene therapy, cell cycle regulation and pharmacotherapeutics to define and validate regenerative

94 is a promising target for the development of pharmacotherapeutics to treat substance use disorders.

95 Recent successes in the pharmacotherapeutic treatment of breast cancer are assoc

96 homeostasis represent viable candidates for pharmacotherapeutic treatment of psychostimulant relapse

97 iplatelet agents necessary components of the pharmacotherapeutic treatment paradigm for these patient

98 The development of pharmacotherapeutic treatments of psychostimulant abuse

99 the goal of developing potential Alzheimer's pharmacotherapeutics, we have synthesized a series of no